A new continuous OC that eliminates menstruation throughout the entire year has been shown to improve dysmenorrhea in a 1-year clinical trial presented at this year's ASRM meeting in Montreal.
A new continuous OC that eliminates menstruation throughout the entire year has been shown to improve dysmenorrhea in a 1-year clinical trial presented at this year's ASRM meeting in Montreal. The phase 3 study evaluated the effects of 20 μg of ethinyl estradiol and 90 μg of levonorgestrel in healthy women between the ages of 18 and 49 with a history of cycle-related symptoms, PMS, or dysmenorrhea. The OC significantly improved symptoms and boosted work productivity.
The researchers, who were supported by a grant from Wyeth, also concluded that the OC was more effective than selective serotonin reuptake inhibitors in treating PMS.
A related study, in which investigators did endometrial biopsies on the same group of women at baseline and 13 months into the trial, found that "histologic changes ....were consistent with a decrease in endometrial growth and decidualization."
Johnson JV, Grubb GS. Endometrial histology in subjects on a continuous use regimen of levo-norgestrel/ethinyl estradiol: results of a Phase 3 study. Fertil Steril. 2005;84(suppl 1):S170.
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Genetics associated with reproductive traits and uterine leiomyomata
April 17th 2024Investigating genetic correlations and shared loci sheds light on potential causal relationships between reproductive traits and uterine leiomyomata, offering insights into their complex interplay and urging further mechanistic exploration.
Read More
Study finds reduced CIN3+ risk from early HPV vaccination
April 16th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
Read More